Paclitaxel Induced MDS and AML: A Case Report and Literature Review
Therapy related acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) have been classically linked to alkylating agents and topoisomerase inhibitors. They constitute about 1% of all AMLs. There is less evidence on association of taxanes (paclitaxel and docetaxel) with these myeloid ne...
Saved in:
| Main Authors: | Udit Bhaskar Bhatnagar, Daulath Singh, Alexy Glazyrin, Jill Moormeier |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2016/8308179 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies
by: Marwah M. Albakri, et al.
Published: (2025-08-01) -
The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS
by: Nanni Schmitt, et al.
Published: (2025-08-01) -
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
by: Jan Philipp Bewersdorf, et al.
Published: (2025-06-01) -
Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
by: David A. Sallman, et al.
Published: (2025-07-01) -
Humanized mouse models in MDS
by: Raluca Munteanu, et al.
Published: (2025-07-01)